Pfizer, by contrast, appears diversified but diffuse—its pipeline may contain value, but that value is not yet organized into ...

In today’s Pharmaceutical Executive Daily, Eli Lilly enters a $7 billion agreement to acquire Kelonia Therapeutics, the Trump ...

The Trump administration’s new executive order aims to accelerate FDA review of psychedelic therapies for mental health ...

The deal secures Lilly an in vivo gene therapy platform that could make CAR-T cell therapies accessible to a far broader ...

A meaningful US access gap persists for off-patent biologics lacking viable biosimilar programs, especially mid-tier products ...

Depth-of-response measures, including MRD and symptom endpoints, reinforced broad clinical benefit beyond PFS, supporting consideration as a new second-line standard for eligible patients. Infection ...

FDA required additional post-approval evaluation of myocardial infarction, stroke, and other cardiovascular events because ...

In a conversation with Pharmaceutical Executive, Morten Graugaard, CEO, Orbis Medicines, discussed FDA’s approval of Icotyde ...

However, President Trump posted on his Truth Social account this morning that he is “pleased to announce the new leadership ...

Grosberg holds a Bachelor of Science in Statistics from the College of Humanities and Social Sciences and a Master of Public ...

Lilly’s Foundayo is reportedly off to a strong start. The company’s obesity only recently hit the market, and a report from ...

Exclusive global rights (excluding mainland China, Hong Kong, and Macau) position AbbVie to integrate Haisco’s early-stage ...